ACCC COVID-19 Resource Center & Discussion Group
for Insights on Providing Optimal Patient Care During the Pandemic.
Providing a VOICE for the MULTIDISCIPLINARY CANCER CARE TEAM and the PATIENTS THEY SERVE since 1993
Meetings & Education
State Society Education Series
NCOA Advocacy Support
Patient Advocacy Organizations
State & Federal Resources
Off-Label Use Literature
Find A Clinical Trial
National Professional Organizations
Financial Advocacy & Patient Assistance
NCOA Corporate Members
Become a Corporate Member
Industry News Archive
COVID-19 Featured Resources
FDA Expands Pembrolizumab Indication to Include First-Line NSCLC Treatment
On April 11, 2019, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck Inc.) for the first-line treatment of patients with stage III non-small cell lung cancer (NSCLC) who are not candidates for surgical resection or definitive chemoradiation or metastatic NSCLC. Patients’ tumors must have no EGFR or ALK genomic aberrations and express PD-L1 (Tumor Proportion Score [TPS] ≥1%) determined by an FDA-approved test.
Read the FDA press release here.